

APPLICATION FOR PATENT

INVENTORS:

KENNETH MARTIN AND TERESA LEIGH BARR

5


TITLE:

BEVERAGE AND ADDITIVE FOR INFLAMED TISSUE

10

Certificate of Express Mail

I hereby certify that this correspondence is being deposited by me with the United States Postal Service as "Express Mail Post Office to Addressee" Express Mail No ET 838 961 061 US in an envelope addressed to MAIL STOP PATENT APPLICATION; Commissioner for Patents; PO Box 1450; Alexandria, VA, 22313-1450, on the following date: JULY 30, 2003


Christian N. Heausler

15

SPECIFICATION

FIELD OF THE INVENTION

[0001] The present invention is a beverage used to treat an inflammatory tissue or arthritic condition in a mammal involving tissue that is underperfused tissue, inflamed joints, or inflamed muscles. The present invention is also a beverage additive in which those who suffer from inflammatory tissues or arthritic conditions can easily receive their daily dosage to ease their pain.

BACKGROUND OF THE INVENTION

[0002] This application is a continuation-in-part of co-pending U.S. Patent Application Serial No 10/241,542 filed September 11, 2002, and claims priority from same. U.S. Patent Application Serial No 10/241,542 is hereby incorporated by reference

[0003] A need has existed for a large convenient dosage, that is not in a solid form, of glucose, chondroitin, a member of the family of araliaceae, and a calcium containing component to be taken in one daily dose that can be quickly absorbed into the bloodstream, thereby bypassing the gut and eliminating the adverse reactions to the elemental ingredients, as well as protecting and buffering the lining of the stomach from the high dosages of the ingredients. The one daily dose also needs to buffer the glucose levels in the blood, thereby significantly reducing or eliminating the adverse effects of the essential ingredients. This makes it possible to administer a one time daily large dose that is fast-absorbing, using a powerful vasodilatation system, is tasteless in most liquids, odorless, non-steroidal, and has no adverse symptoms of nausea, heartburn, diarrhea, constipation or headache. The daily dose needs to perfuse underperfused tissue by saturating the tissue, increasing mobility of a mammal in all directions, decreasing inflammation, maintaining cartilage viability, and increasing strength, muscle flexibility and endurance. The daily dose also needs to be cost effective and capable of mass production.

- [0004] Petrus US Patent No 6,399,093 discloses a method and composition for the treatment of musculoskeletal disorders in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agents to provide anti-inflammatory relief and analgesia to the applied body part.
- 5
- [0005] Falk US Patent Nos 5,827,834; 5,852,002; 5,929,048; and 5,932,560 refer to methods of using MSM, hyaluronic acid, and glucosamine to reduce the swelling of brain tumors in a similar manner as Falk US Patent No 6,194,392.
- [0006] The present invention has been designed to be beneficial because it is fast-absorbing, tasteless, odorless, non-steroidal, and a vasodilator. The invention additive also is a one-time daily large dose. There are no symptoms of nausea, heartburn, constipation, diarrhea, and headaches associated with the present invention. In addition, the present invention contains a high quantity of glucose and a high quantity of chondroitin.
- 10
- [0007] The beverage of the present invention is also cost effective since it is capable of being mass-produced. An eight ounce or twelve ounce beverage can contain the single serving daily dose.
- 15
- [0008] The present invention is also beneficial because it perfuses underperfused tissues. This means the additive saturates the tissue, increases mobility in all directions, decreases inflammation, maintains cartilage viability, increases strength, increases muscle flexibility, and increases endurance.
- 20

SUMMARY OF THE INVENTION

- [0009] The invention relates to a beverage that is an ingestible fluid and a dosage amount of an ingestible composition. The ingestible composition is a composition for treating an inflammatory tissue in a mammal, such as underperfused tissue, inflamed joints, inflamed muscles. The dosage composition includes a glucose ingredient, such as
- 25

5 glucosamine sulfate, glucosamine hydrochloride, n-acetyl glucosamine, and combinations thereof; a chondroitin component, such as chondroitin sulfate, chondroitin hydrochloride, and combinations thereof; a member of the family of araliaceae; calcium containing component; and a sulfonate having at least one methyl group ingesting the beverage. The family of araliaceae is used for buffering the ingestion of the glucose ingredient. The araliaceae is a member of the ginseng group, such as American ginseng, Siberian ginseng, panax ginseng, and combinations thereof.

10 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

- [00010] Before explaining the present invention in detail, it is to be understood that the invention is not limited to the particular embodiments and that it can be practiced or carried out in various ways.
- 15 [00011] The invention is a beverage made of an ingestible fluid and a dosage amount of an ingestible composition for treating an inflammatory tissue or arthritic condition in a mammal involving tissue that is underperfused tissue, inflamed joints, or inflamed muscle.
- 20 [00012] The dosage amount of the beverage is made from a glucose component such as a glucosamine sulfate, a glucosamine hydrochloride, an n-acetyl glucosamine, and combinations thereof.
- 25 [00013] The dosage amount of the beverage includes a chondroitin component such as a chondroitin sulfate, a chondroitin hydrochloride, and combinations thereof.
- [00014] The dosage amount of the beverage includes a member of the family of araliaceae for buffering the ingestion of the glucose ingredient, such as American ginseng, Siberian ginseng, panax ginseng, and combinations thereof.
- [00015] The dosage amount of the beverage further includes a calcium containing component. The calcium containing component can include calcium carbonate, calcium citrate,

coral calcium, or combinations thereof. The dosage amount of the calcium component can include from about 10 mg to about 1000 mg.

[00016] The dosage amount of the beverage further includes a sulfonate having at least one methyl group. The preferred dosage is between 10 mg and 3000 mg. The preferred sulfonate with at least one methyl group is methyl sulfonyl methane (MSM).

5 [00017] The beverage can further include a lubricating sodium agent.

[00018] In the beverage, the invention contemplates variations in the dosage amounts. A preferred dosage amount is 1000 mg to 2000 mg of a glucose ingredient, 10 mg to 1500 mg of a chondroitin component, 5 mg to 800 mg of a member of the family of araliaceae, 10 mg to 1500 mg of a calcium containing component, and 10mg to 3000mg of the sulfonate with at least one methyl group.

10 [00019] The dosage amount of the beverage can further include from about 10 mg to about 3000 mg of Vitamin C.

15 [00020] The dosage amount of the beverage can further include from about 10 mg to about 20 mg of Vitamin B₃. Examples of B₃ Vitamins contemplated in the beverage are a vasodialating niacin, a vasodialating niacinamide, and combinations thereof.

20 [00021] The fluid in the ingestible fluid of the beverage can be water, coffee, tea, artificial drinks, alcoholic fluids, non-alcoholic fluids, fruit juice, vegetable juice, blends of juice, juice and water blends, concentrates of juice, soda, sports drinks, and combinations thereof. The invention contemplates that any fluid normally ingested by people is acceptable for the beverage.

25 [00022] The invention is a method for treating an inflammatory tissue that is underperfused tissue, inflamed joints, or inflamed muscle, the method consists of ingesting a beverage made of an ingestible fluid and a dosage amount of an ingestible composition. The method ends by ingesting the beverage.

[00023] The glucose component in the method can be a glucosamine sulfate, a glucosamine hydrochloride, an n-acetyl glucosamine, and combinations thereof. The chondroitin

component can be a chondroitin sulfate, a chondroitin hydrochloride, and combinations thereof.

- 5 [00024] The member of the family of araliaceae is used for buffering the ingestion of the glucose ingredient. The preferred member of the family of araliaceae is ginseng. Types of ginseng contemplated by the method include as American ginseng, Siberian ginseng, panax ginseng, and combinations thereof.
- 10 [00025] The method of providing a beverage comprises using a calcium containing component, such as calcium carbonate, calcium citrate, coral calcium, or combinations thereof. The preferred dosage of the calcium containing component is between about 10 mg and about 1000 mg.
- 15 [00026] The method of providing the beverage can include the step of using a dosage amount of 1000 mg to 2000 mg of a glucose ingredient, 10 mg to 1500 mg of a chondroitin component, 5 mg to 800 mg of a member of the family of araliaceae, 10 mg to 1500 mg of a calcium containing component, and 10mg to 3000mg of the sulfonate with at least one methyl group.
- [00027] The method can include using from about 10 mg to about 3000 mg of Vitamin C.
- [00028] The method of providing the beverage can include using from about 10 mg to about 20 of a Vitamin B₃, such as a vasodialating niacin, vasodialating niacinamide, and combinations thereof.
- 20 [00029] The method of providing the beverage can include using a member of an ingestible fluid selected from the group consisting of water, coffee, tea, artificial drinks, alcoholic fluids, non-alcoholic fluids, fruit juice, vegetable juice, blends of juice, juice and water blends, concentrates of juice, soda, sports drinks, and combinations thereof.
- 25 [00030] While this invention has been described with emphasis on the preferred embodiments, it should be understood that within the scope of the appended claims, the invention might be practiced other than as specifically described herein.